Humacyte (HUMA) Financials: History & Chart

Humacyte, Inc.(HUMA)

Biotechnology · Durham, NC

$0.49-0.01 (-1.80%)

Delayed quote: Oct 6, 2026, 2:25 PM EDT

About Humacyte, Inc.

Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.

Durham, NC

184 employees

www.humacyte.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Laura E. Niklason

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	2.12M	406K	495K	467K	753K	301K	517K	7.23M	0.00
Cost of Goods Sold	16.26M	1.23M	2.04M	10.87M	2.13M	2.07M	1.98M	3.61M	1.81M
Gross Profit	-14.14M	-825K	-1.54M	-10.40M	-1.37M	-1.77M	-1.46M	3.61M	-1.81M
Gross Profit Margin	-666.8%	-203.2%	-311.7%	-2227.6%	-182.2%	-588.7%	-282.8%	50.0%	N/A
Total Operating Expenses	97.01M	26.17M	27.39M	20.43M	23.02M	27.95M	21.72M	31.70M	28.42M
Research & Development	69.48M	18.14M	19.46M	14.61M	17.27M	22.01M	15.42M	20.66M	22.93M
Selling, General & Administrative	27.53M	8.03M	7.93M	5.83M	5.75M	7.81M	8.14M	11.05M	7.31M
Operating Income (EBIT)	-111.16M	-27.00M	-28.93M	-30.84M	-24.39M	-29.73M	-23.18M	-28.09M	-30.23M
Operating Margin	-5240.8%	-6649.3%	-5845.5%	-6603.0%	-3239.0%	-9876.1%	-4484.3%	-388.6%	N/A
Income Before Tax (EBT)	-96.73M	-36.80M	-17.62M	-24.80M	-17.51M	-37.66M	39.14M	-20.94M	-39.20M
Interest Income	1.81M	388K	330K	503K	590K	832K	662K	852K	911K
Interest Expense	10.30M	2.32M	2.27M	3.09M	2.61M	2.54M	3.00M	2.51M	2.44M
Other Income/Expense	14.42M	-9.81M	11.32M	6.03M	6.88M	-7.93M	62.32M	7.15M	-8.97M
Net Income	-96.73M	-36.80M	-17.62M	-24.80M	-17.51M	-37.66M	39.14M	-20.94M	-39.20M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-4560.8%	-9064.5%	-3559.4%	-5311.3%	-2325.4%	-12511.0%	7570.4%	-289.7%	N/A
EBITDA	-104.38M	-25.66M	-27.14M	-29.05M	-22.52M	-27.87M	-21.35M	-26.28M	-28.42M
EBITDA Margin	-4921.1%	-6320.0%	-5483.8%	-6220.1%	-2991.4%	-9258.1%	-4130.0%	-363.6%	N/A
Depreciation & Amortization	6.78M	1.34M	1.79M	1.79M	1.86M	1.86M	1.83M	1.81M	1.81M
EPS Basic	-0.51	-0.16	-0.09	-0.15	-0.11	-0.24	0.28	-0.16	-0.33
EPS Diluted	-0.51	-0.16	-0.09	-0.15	-0.11	-0.24	0.28	-0.16	-0.33
Weighted Average Basic Shares	234.18M	234.18M	197.85M	158.16M	158.31M	155.44M	131.50M	118.48M	119.41M
Weighted Average Diluted Shares	234.18M	234.18M	197.85M	158.16M	158.31M	155.44M	131.76M	118.48M	119.41M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Revenue	2.04M	0.00	0.00	1.56M	1.26M	1.49M	6.19M
Cost of Goods Sold	17.05M	7.19M	76.55M	8.26M	61.34M	54.08M	75.60M
Gross Profit	-15.01M	-7.19M	-76.55M	-6.69M	-60.08M	-52.59M	-69.42M
Gross Profit Margin	-736.5%	N/A	N/A	-427.5%	-4756.8%	-3527.0%	-1122.0%
Total Operating Expenses	92.43M	107.21M	23.50M	77.89M	21.13M	12.01M	16.27M
Research & Development	69.30M	88.60M	76.55M	63.26M	61.34M	54.08M	75.60M
Selling, General & Administrative	31.17M	25.80M	20.39M	22.88M	21.13M	12.01M	16.27M
Operating Income (EBIT)	-107.44M	-114.40M	-100.05M	-84.58M	-81.21M	-64.60M	-85.69M
Operating Margin	-5271.7%	N/A	N/A	-5404.3%	-6429.8%	-4332.7%	-1385.0%
Income Before Tax (EBT)	-40.83M	-148.70M	-110.78M	-11.96M	-26.48M	-66.52M	-85.42M
Interest Income	2.59M	4.10M	5.47M	2.63M	16K	278K	269K
Interest Expense	11.25M	9.28M	6.60M	6.20M	4.35M	2.20M	2.30M
Other Income/Expense	66.60M	-34.30M	-10.73M	72.61M	54.73M	-1.92M	269K
Net Income	-40.83M	-148.70M	-110.78M	-11.96M	-26.48M	-66.52M	-85.42M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-2003.6%	N/A	N/A	-764.5%	-2096.4%	-4461.7%	-1380.7%
EBITDA	-100.09M	-107.21M	-92.33M	-76.37M	-72.97M	-56.25M	-78.94M
EBITDA Margin	-4911.3%	N/A	N/A	-4879.7%	-5777.3%	-3772.6%	-1275.9%
Depreciation & Amortization	7.34M	7.19M	7.72M	8.21M	8.24M	8.35M	6.75M
EPS Basic	-0.26	-1.26	-1.07	-0.12	-0.66	-5.52	N/A
EPS Diluted	-0.26	-1.26	-1.07	-0.12	-0.66	-5.52	N/A
Weighted Average Basic Shares	158.16M	118.48M	103.42M	103.05M	39.97M	12.45M	103.00M
Weighted Average Diluted Shares	158.16M	118.48M	103.42M	103.05M	39.97M	12.45M	103.00M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.